We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Nayanacare is a mobile and pc app that allows individual customers to make the right choice of care services and carers quick and easy. Care suppliers can reduce costs by using Nayanacare as a dedicated marketing platform and take advantage of the platforms business management capabilities.
days to go: Expired investment: £76,030
Aerobit is a smart inhaler, a tool for tracking medication use that records each time inhalers are taken and comes in a variety of cool toy designs. Built in sensors can even tell if the inhaler has been shaken correctly. 
days to go: Expired investment: £116,960
Thermulon builds aerogels for building insulation and aspires to disrupt the global thermal building insulation market that was worth $30 billion in 2020. It claims that its aerogels are the first to beat the tradeoff between fire safety, thermal performance and price with the ability to fight climate and fire-safety emergencies. Thermulon cites its research with Ryder Architecture stating that using Thermulon's products on a new apartment block could save 100mm in insulation thickness compared to mineral wood and potentially add floor space equivalent to 7 additional 1-bed flats making safe insulation a profitable move for developers. The company was awarded £550,000 in InnovateUK equity-free grants, garnered a project to insulate 10,000 social houses over the next 5-10 years, and has been felicitated with awards from the Royal Society of Chemistry and the Royal Academy of Engineering. The company states it will use the investment to grow its team, file its first patent, certify its product and get Thermulon’s insulation on walls.
days to go: Expired investment: £949,033
Providing convenient and affordable healthcare to patients either at home or their workplace. Practitioners can visit patients and offer a range of medical treatments including vaccinations, testing, physiotherapy and primary care. Qured have been highly successful in London and are growing at an alarming rate, ready to help the whole of the UK.
days to go: Expired investment: £763,160
Doctors available 24 hours a day, 365 days a year to visit, diagnose, treat, refer and prescribe medication as needed. No membership fees or hidden costs.
days to go: Expired investment: £540,695
Please watch the video for more information
days to go: Expired investment: £328,193
Please watch the video for more information
days to go: Expired investment: £376,618
Advanced Blast & Ballistic Systems (ABBS) is a company that has developed globally patented systems to counteract the forces an armoured vehicle sustains when a mine or Improvised Explosive Device (IED) explodes under it. ABBS asserts that mines and IEDs accounted for over 80% of UK and US army casualties in Iraq and Afghanistan. ABBS aims to change this and become a major contender in the $20 billion armoured vehicle protection market. The company points out that it has been tasked by the European Union Aviation Safety Agency (EASA) and European Organisation for Civil Aviation Equipment (EUROCAE) to draft safety regulations for emergency descent arrest systems. The company also holds multiple patents for its proven Vehicle Global Acceleration Mitigation (VGAM) vehicle mine protection system and has a patent pending for a Zero-Zero Crash Prevention (ZZCP) system for light aircraft and electric Vertical Takeoff and Landing (eVTOLs) systems. It will use the investment for marketing, boosting R&D, and maintaining and expanding its IP/patent portfolio.
days to go: Expired investment: £88,003
Advanced Blast & Ballistic Systems (ABBS) develops patented systems to counteract the forces an armoured vehicle sustains when a mine or Improvised Explosive Device (IED) explodes under it. ABBS asserts that mines and IEDs accounted for over 80% of UK and US army casualties in Iraq and Afghanistan. ABBS argues that its systems can reverse this scenario. It aspires to become a contender in the $20 billion armoured vehicle protection market. The company has been tasked by the European Union Aviation Safety Agency (EASA) and European Organisation for Civil Aviation Equipment (EUROCAE) to draft safety regulations for emergency descent arrest systems. It also holds multiple patents for its proven Vehicle Global Acceleration Mitigation (VGAM) vehicle mine protection system and has a patent pending for a Zero-Zero Crash Prevention (ZZCP) system for light aircraft and electric Vertical Takeoff and Landing (eVTOLs) systems. ABBS will use the investment for marketing, boosting R&D, and maintaining and expanding its IP/patent portfolio.
days to go: Expired investment: £297,534
Ablatus Therapeutics is a MedTech company developing a one-of-a-kind tissue ablation platform known as Bimodal Electric Tissue Ablation (BETA). This technology has been designed to overcome the limitations of existing products by offering ablation solutions in oncology (tumours) as well as non-oncology targets. With the proceeds, the company will finish the final elements of engineering of the generator and probe. It will also deliver formal safety test data that is a prerequisite for subsequent clinical trials.
days to go: Expired investment: Withheld
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph